So far, four vaccines against the corona virus have been approved in the EU countries.
Now a fifth could follow.
The vaccine differs from its predecessors in one decisive point.
Amsterdam - The US manufacturer Novavax has applied for market approval in the EU for its corona vaccine.
This was announced by the responsible European Medicines Agency EMA on Wednesday in Amsterdam.
also read
EMA recommends booster vaccination if the immune system is weak
For people with a weak immune system, a third vaccination is advisable after just 28 days, explains the European Medicines Agency.
The ability to form antibodies is thus improved.
EMA recommends booster vaccination if the immune system is weak
Sweden suspends Moderna vaccine in younger people
Could Moderna vaccination increase the risk of heart inflammation?
The Swedish health authority is suspending the vaccine in children under 30 for the time being.
Sweden suspends Moderna vaccine in younger people
Curevac withdraws vaccine candidates
The biotech company Curevac is stopping its first Covid vaccine and withdrawing the vaccine from the approval process.
The company now wants to lead the way with a modified vaccine.
Curevac withdraws vaccine candidates
A team of experts will now check the manufacturer's data and weigh risks against benefits.
A decision is expected in a few weeks, as the EMA announced.
The experts had already evaluated studies on the effect in the ongoing test procedure.
A preliminary examination of possible risks has also been concluded.
If the EMA recommends conditional marketing authorization, the EU Commission still has to give its final approval.
But that is a matter of form.
So far, four vaccines have been approved in the EU.
The Novavax product called Nuvaxovid (NVX-CoV2373), unlike the vaccines approved to date, is neither an mRNA vaccine - like the preparations from Biontech and Moderna - nor a vector vaccine like those from Astrazeneca and Johnson & Johnson: The vaccine contains tiny particles made up of a laboratory-made version of the Sars-CoV-2 spike protein.
Like all vaccines, Nuvaxovid is designed to prepare the immune system for a possible infection.
dpa
